<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        338-334-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESOBLOC 10 mg/ml solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESMOLOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Esobloc contains a medicine called esmolol. It belongs to a group of medicines called &lsquo;beta-blockers&rsquo;. It works by controlling the rate and force of your heartbeat. It can also help to reduce your blood pressure.</p><p>It is used to treat:</p><ul><li>Heartbeat problems, when your heart beats too fast.</li><li>Heartbeat problems and an increase in your blood pressure if this happens during or straight after an operation.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Your doctor will not give you Esobloc if: </strong></p><ul><li>You are allergic to esmolol, to other beta-blocker medicines, or any of the other ingredients of this medicine (listed in section 6). The signs of an allergic reaction include shortness of breath, wheezing, rash, itching or swelling of your face and lips.</li><li>You have a very slow heartbeat (less than 50 beats per minute).</li><li>You have a fast or alternating fast and slow heartbeat.</li><li>You have something called &ldquo;severe heart block&rdquo;. Heart block is a problem with the electrical messages that control your heartbeat.</li><li>You have low blood pressure.</li><li>You have a problem with the blood supply to your heart.</li><li>You have serious heart failure symptoms.</li><li>You are receiving or have recently received verapamil. You must not be given Esobloc within 48 hours of when you stop receiving verapamil.</li><li>You have a gland disease called phaeochromocytoma which has not been treated. Phaeochromocytoma arises from the adrenal gland and may cause a sudden increase in blood pressure, severe headache, sweating and increased heartbeat.</li><li>You have increased blood pressure in the lungs (pulmonary hypertension).</li><li>You have asthma symptoms that are worsening rapidly.</li><li>You have increased levels of acids in your body (metabolic acidosis).</li></ul><p>You will not be given Esobloc if any of the above applies to you. If you are not sure if you have any of these conditions, talk to your doctor or nurse before having Esobloc.</p><p><strong>&nbsp;Warnings and precautions </strong></p><p>Talk to your doctor, nurse or pharmacist before being given Esobloc. Your doctor will take special care with this medicine if:</p><ul><li>You are being treated for certain heart rhythm disorders called supraventricular arrhythmias and you:</li></ul><p>-&nbsp;Have other heart problems or</p><p>-&nbsp;Are taking other heart medicines.</p><p>Use of esmolol in this way can lead to severe reactions which may be fatal including:</p><p>-&nbsp;Loss of consciousness</p><p>-&nbsp;Shock (when your heart does not pump enough blood)</p><p>-&nbsp;Heart attack (cardiac arrest).</p><ul><li>You develop low blood pressure (hypotension). The signs of this may be feeling dizzy or light headed, especially when standing up. Low blood pressure usually gets better within 30 minutes of the end of your Esobloc treatment.</li><li>You have a low heart rate before treatment.</li><li>Your heart rate decreases to less than 50 to 55 beats per minute. If this happens your doctor may give you a lower dose or stop treatment with Esobloc.</li><li>You have heart failure.</li><li>You have problems with the electrical messages that control your heartbeat (heart block).</li><li>You have a gland disease called phaeochromocytoma which has been treated with medicines called alpha-receptor blockers.</li><li>You are being treated for high blood pressure (hypertension) which has been caused by low body temperature (hypothermia).</li><li>You have narrowing of your airways or wheezing, such as with asthma.</li><li>You have diabetes or low blood sugar. Esmolol can increase the effects of your diabetes medicines.</li><li>You develop skin problems. These can be caused by the solution leaking around the site of the injection. If this happens your doctor will use a different vein for your injection.</li><li>You have a particular type of angina (chest pain) called &lsquo;Prinzmetal&rsquo;s angina&rsquo;.</li><li>You have low blood volume (with low blood pressure). You could develop circulatory collapse more easily.</li><li>You have circulation problems, such as paleness of your fingers (Raynaud&rsquo;s disease) or aching, tired and sometimes burning pains in your legs.</li><li>You have kidney problems. If you have kidney disease or you need kidney dialysis you could develop high blood potassium levels (hyperkalemia). This can cause serious heart problems.</li><li>You have any allergies or are at risk of anaphylactic reactions (severe allergic reactions). Esmolol can make allergies more severe and more difficult to treat.</li><li>You or any of your family have a history of psoriasis (where your skin produces scaly patches).</li><li>You have a disease called hyperthyroidism (an overactive thyroid gland).</li></ul><p>Changing the dose is not usually necessary if you have liver problems.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before being given this medicine. You may need to be checked carefully and your treatment may be changed.</p><p><strong>&nbsp;Other medicines and Esobloc</strong></p><p>Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you have obtained yourself, without a prescription, including herbal medicines and natural products. Your doctor will check that any other medicines you are taking will not alter the way that Esobloc works.</p><p>&nbsp;In particular, tell your doctor or nurse if you are taking any of the following:</p><ul><li>Medicines that can lower the blood pressure or slow the heart rate.</li><li>Medicines used to treat heart rhythm problems or chest pain (angina) such as verapamil and diltiazem. You should not receive Esobloc within 48 hours of stopping verapamil.</li><li>Nifedipine, which is used to treat chest pain (angina), high blood pressure and Raynaud&rsquo;s disease.</li><li>Medicines used to treat heart rhythm problems (such as quinidine, disopyramide, amiodarone) and heart failure (such as digoxin, digitoxin, digitalis).</li><li>Medicines used to treat diabetes, including insulin and medicines taken by mouth.</li><li>Medicines known as ganglion blocking agents (such as trimetaphan).</li><li>Medicines used as pain killers, such as non-steroidal anti-inflammatory drugs known as NSAIDs.</li><li>Floctafenine, which is a pain killer.</li><li>Amisulpride, a medicine that is used to treat mental problems.</li><li>&lsquo;Tricyclic&rsquo; antidepressant medicines (such as imipramine and amitriptyline) or any other drugs for mental health problems.</li><li>Barbiturates (such as phenobarbital, used to treat epilepsy) or phenothiazines (such as chlorpromazine, used to treat mental disorders).</li><li>Clozapine which is used to treat mental disorders.</li><li>Epinephrine, which is used to treat allergic reactions.</li><li>Medicines used to treat asthma.</li><li>Medicines used to treat colds or a blocked nose, called &lsquo;nasal decongestants&rsquo;.</li><li>Reserpine, which is used to treat high blood pressure.</li><li>Clonidine, which is used to treat high blood pressure and migraine.</li><li>Moxonidine, which is used to treat high blood pressure.</li><li>Ergot derivates, medicines mainly used to treat Parkinson&rsquo;s disease.</li><li>Warfarin, which is used to thin your blood.</li><li>Morphine, which is a strong pain killer.</li><li>Suxamethonium chloride (also known as succinylcholine or scoline) or mivacurium, which are used to relax your muscles, usually during an operation. Your doctor will also take special care when using Esobloc during operations, when you will be having anaesthetics and other treatments.</li></ul><p>If you are not sure if any of the above applies to you talk to your doctor, nurse or pharmacist before having Esobloc.</p><p><strong>&nbsp;</strong><em>Tests you may have while Esobloc used</em></p><p>The use of medicines such as Esobloc over a long period of time can cause a reduction in the force of your heartbeat.</p><p><strong>&nbsp;</strong>Since Esobloc is only used for a limited time, this is unlikely to happen to you. During treatment you will be carefully monitored and Esobloc treatment will be reduced or stopped if the force of your heartbeat is reduced.</p><p>Your doctor will also check your blood pressure while you are being treated with Esobloc.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>You should not be given Esobloc if you are pregnant, or if you think you may be pregnant.</p><p>Tell your doctor if you are breast-feeding. Esmolol may pass into breast milk, so you should not be given Esobloc if you are breast-feeding.</p><p><strong>Esobloc<strong> </strong>contains sodium </strong></p><p>Esobloc contains sodium. Each vial contains 0.206 mmol (4.738 mg) sodium.<strong> </strong>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The recommended dose</strong></p><p>Your doctor will decide how much of the medicine you will need and for how long it will be given to you. Esobloc will not normally be given for longer than 24 hours.</p><p><strong>How Esobloc is given</strong></p><p>Esobloc is ready to use. You will be given Esobloc by a slow injection (infusion) through a needle inserted into a vein in your arm.</p><p>Esobloc must not be mixed with sodium bicarbonate or other medicinal products.</p><ul><li>The treatment is given in two stages:</li></ul><p>-&nbsp;&nbsp;Stage one: a large dose is given over one minute. This increases the levels in your blood quickly. &nbsp;</p><p>-&nbsp;Stage two: a smaller dose is then given over four minutes. &nbsp;</p><p>-&nbsp;Stage one and two may then be repeated and adjusted according to your heart&rsquo;s response. As soon as an improvement has happened, stage one (the large dose) will be stopped and stage two (the small dose) will be reduced as necessary. &nbsp;</p><p>-&nbsp;&nbsp;After reaching a stable condition, you may be given another heart drug, while your dose of Esobloc is gradually reduced.</p><ul><li>If your heart rate or blood pressure increases during an operation or straight after recovering from it, you will be given larger doses of Esobloc for a short time.</li></ul><p><strong>Elderly</strong></p><p>Your doctor will start your treatment with a lower dose.</p><p><strong>&nbsp;Children</strong></p><p>Children up to the age of 18 years should not receive Esobloc .</p><p><strong>&nbsp;If you take more Esobloc than you should</strong></p><p>As you are being given Esobloc by a trained and qualified person, it is unlikely that you will have too much. However, if this happens the doctor will stop Esobloc and give you additional treatment, if necessary.</p><p><strong>&nbsp;If you forget to take Esobloc</strong></p><p>As you are being given Esobloc by a trained and qualified person, it is unlikely that you will miss a dose. However, if you think that you have missed a dose, talk to your doctor, nurse or pharmacist as soon as possible.</p><p><strong>If you stop taking Esobloc</strong></p><p>Suddenly stopping Esobloc may cause symptoms of rapid heartbeat (tachycardia) and high blood pressure (hypertension) to return. To avoid this your doctor should stop your treatment gradually. If you are known to have coronary artery disease (this may be associated with a history of angina or heart attack) your doctor will take special care when stopping treatment with Esobloc.</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects disappear within 30 minutes of stopping treatment with esmolol.</p><p><strong><em>The following side effects have been reported with esmolol: </em></strong></p><p>Tell your doctor or nurse straight away if you notice any of the following side effects, which can be serious. The infusion may also need to be stopped.</p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><ul><li>Fall in blood pressure. This can be rapidly corrected by reducing the dose of esmolol or stopping the treatment. Your blood pressure will be measured often during treatment.</li><li>Excessive sweating. &nbsp;</li></ul><p><strong>Common </strong>(may affect less than 1 in 10 people)</p><ul><li>Loss of appetite.</li><li>Feeling anxious or depressed.</li><li>Dizziness.</li><li>Feeling sleepy.</li><li>Headache.</li><li>Tingling or &lsquo;pins and needles&rsquo;.</li><li>Difficulty concentrating.</li><li>Feeling confused or agitated.</li><li>Feeling or being sick (nausea and vomiting).</li><li>Feeling weak.</li><li>Feeling tired (fatigue).</li><li>Irritation and hardening of your skin where esmolol was injected.</li></ul><p><strong>Uncommon </strong>(may affect less than 1 in 100 people)</p><ul><li>Abnormal thoughts.</li><li>Sudden loss of consciousness.</li><li>Feeling faint or fainting.</li><li>Fits (seizures or convulsions).</li><li>Problems with speech.</li><li>Problems with eyesight.</li><li>Slow heart rate.</li><li>Problems with the electrical messages that control your heartbeat.</li><li>Increased pressure in the arteries of the lungs.</li><li>Inability of the heart to pump enough blood (heart failure).</li><li>A disruption in the rhythm of the heart sometimes known as palpitations (ventricular extrasystoles).</li><li>A heartbeat disorder (nodal rhythm).</li><li>Chest discomfort caused by poor blood flow through the blood vessels of the heart muscle (angina pectoris).</li><li>Poor circulation in your arms or legs.</li><li>Looking pale or flushed.</li><li>Fluid on your lungs.</li><li>Shortness of breath or tightness of the chest making it difficult to breathe.</li><li>Wheezing.</li><li>Blocked nose.</li><li>Abnormal rattling/crackling sounds when breathing.</li><li>Changes in your sense of taste.</li><li>Indigestion.</li><li>Constipation.</li><li>Dry mouth.</li><li>Pain in your stomach area.</li><li>Discoloured skin.</li><li>Reddening of the skin.</li><li>Pain in your muscles or tendons, including around the shoulder blades and ribs.</li><li>Problems passing urine (urinary retention).</li><li>Feeling cold or high temperature (fever).</li><li>Pain and swelling (oedema) of your vein where esmolol was injected.</li><li>Burning feeling or bruising at the site of injection.</li></ul><p><strong>Very rare </strong>(may affect less than 1 in 10,000 people)</p><ul><li>Severe reduction in heart rate (sinus arrest).</li><li>No electrical activity in the heart (asystole).</li><li>Tender blood vessels with an area of hot red skin (thrombophlebitis).</li><li>Dead skin caused by the solution leaking around the site of the injection.</li></ul><p><strong>&nbsp;Not known </strong>(the number of people affected is unknown)</p><ul><li>Increased levels of potassium in the blood (hyperkalemia).</li><li>Increased levels of acids in your body (metabolic acidosis).</li><li>Increased rate of contraction of the heart (accelerated idioventricular rhythm).</li><li>Spasm of the artery in the heart.</li><li>Failure of the normal circulation of the blood (cardiac arrest).</li><li>Psoriasis (where your skin produces scaly patches).</li><li>Swelling of the skin of the face, limbs, tongue or throat (angioedema).</li><li>Hives (urticaria).</li><li>Inflammation of a vein or blistering at the site of infusion.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 25&deg;C.</p><p>Store in the original package in order to protect from light. &nbsp;</p><p>The opened product is stable for 24 hours at 2 to 8&deg;C. However, it should be used immediately after opening.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is esmolol hydrochloride. Each 10 ml contains esmolol hydrochloride equivalent to 100 mg esmolol.</p><p>The other ingredients are sodium acetate trihydrate, glacial acetic acid, NaOH and/or HCl and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Esobloc 100 mg/10 ml Solution for Injection is clear, colourless to light yellow solution in 10 ml type I amber glass vials with grey rubber stoppers and aluminum caps. 

Pack size: 1 Vial (10 ml). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2020; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إيزوبلوك على دواء يسمى إيسمولول. وهو ينتمي إلى مجموعة أدوية تُسمى &quot;حاصرات مستقبلات بيتا&quot;. إنه يعمل عن طريق التحكم في معدل ضربات قلبك وقوتها. يمكن أن يساعد أيضاً في خفض ضغط الدم.</p><p>يستخدم في علاج:</p><ul dir="rtl"><li>مشاكل ضربات القلب، عندما ينبض قلبك بسرعة كبيرة.</li><li>مشاكل في ضربات القلب وزيادة في ضغط الدم إذا حدث ذلك أثناء العملية أو بعدها مباشرةً.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لن يعطيك طبيبك إيزوبلوك إذا: </strong></p><ul dir="rtl"><li>كنت تعاني من حساسية لإيسمولول، أو لحاصرات مستقبلات بيتا الأخرى، أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6). من علامات رد الفعل التحسسي تشمل ضيق النفس أو صفير عند التنفس أو طفح أو حكة أو تورم الوجه والشفتين.</li><li>كنت تعاني من ضربات قلب بطيئة جداً (أقل من 50 نبضة في الدقيقة).</li><li>كنت تعاني من ضربات قلب سريعة أو متناوبة بطيئة وسريعة.</li><li>كان لديك ما يُسمى باسم &quot; إحصار القلب الشديد&quot;. إحصار القلب هي مشكلة في الرسائل الكهربائية التي تتحكم في ضربات قلبك.</li><li>كنت مصاباً بانخفاض ضغط الدم.</li><li>كنت تعاني من مشكلة في تدفق الدم لقلبك.</li><li>كان لديك أعراض خطيرة لفشل القلب.</li><li>كنت تأخذ أو أخذت فيراباميل مؤخراً. يُمنع إعطاؤك إيزوبلوك خلال 48 ساعة من التوقف عن أخذ فيراباميل.</li><li>كان لديك مرض في الغدة يسمى ورم القواتم لم يُعالَج. ينشأ ورم القواتم من الغدة الكظرية وقد يتسبب في زيادة مفاجئة في ضغط الدم وصداع حاد وتعرق وزيادة ضربات القلب.</li><li>كنت تعاني من ارتفاع ضغط الدم في الرئتين (ارتفاع ضغط الدم الرئوي).</li><li>كنت تعاني من أعراض الربو التي تزداد سوءاً بسرعة.</li><li>كنت تعاني من زيادة في مستويات الأحماض في جسمك (الحماض الأيضي).</li></ul><p>لن يتم إعطاؤك إيزوبلوك إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكداً مما إذا كان لديك أي من هذه الحالات، فتحدث إلى طبيبك أو ممرضتك قبل أخذ إيزوبلوك.</p><p><strong>&nbsp;الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الممرض أو الصيدلي قبل إعطائك إيزوبلوك. سيقوم طبيبك بأخذ عناية خاصة مع هذا الدواء إذا:</p><ul dir="rtl"><li>كنت تُعالَج من بعض اضطرابات ضربات القلب تسمى اضطرابات نظم القلب فوق البُطين وأنت:</li></ul><p dir="RTL">-&nbsp;تعاني من مشاكل أخرى في القلب أو</p><p dir="RTL">-&nbsp;تأخذ أدوية أخرى للقلب.</p><p dir="RTL">يمكن أن يؤدي استخدام إيسمولول بهذه الطريقة إلى ردود فعل شديدة قد تكون مميتة ومنها:</p><p dir="RTL">-&nbsp;فقدان الوعي</p><p dir="RTL">-&nbsp;الصدمة (عندما لا يضخ قلبك كمية كافية من الدم)</p><p dir="RTL">-&nbsp;أزمة قلبية (توقف القلب).</p><ul dir="rtl"><li>كنت مصاباً بانخفاض ضغط الدم. قد تكون علامات هذا الشعور بالدوار أو خفة الرأس، لا سيما عند الوقوف. يتحسن ضغط الدم عادةً في غضون 30 دقيقة من أخذ إيزوبلوك.</li><li>كنت تعاني من معدل ضربات قلب منخفض قبل العلاج.</li><li>كنت تعاني من انخفاض معدل ضربات قلبك إلى أقل من 50 إلى 55 نبضة في الدقيقة. إذا حدث هذا، فقد يعطيك طبيبك جرعة أقل أو يوقف العلاج باستخدام إيزوبلوك.</li><li>تعاني من فشل في القلب.</li><li>كان لديك مشاكل في الرسائل الكهربائية التي تتحكم في ضربات قلبك (إحصار القلب).</li><li>كان لديك مرض في الغدة يُسمى ورم القواتم والذي تم علاجه بأدوية تسمى حاصرات مستقبلات ألفا.</li><li>كنت تُعالَج من ارتفاع ضغط الدم (فرط ضغط الدم) الناجم عن انخفاض درجة حرارة الجسم (انخفاض حرارة الجسم).</li><li>كان لديك ضيق في مجرى الهواء أو صفير، مثل المصاحب للربو.</li><li>كنت تعاني من مرض السكري أو انخفاض السكر في الدم. يمكن أن يزيد إيسمولول من آثار أدوية مرض السكري التي تأخذها.</li><li>كنت مصاباً بمشاكل جلدية. يمكن أن يحدث ذلك بسبب تسرب المحلول حول موضع الحقن. إذا حدث هذا، فسيستخدم طبيبك وريداً مختلفاً للحقن.</li><li>كنت تعاني من نوع معين من الذبحة (ألم في الصدر) تعرف باسم &rsquo;ذبحة برينزميتال&lsquo;.</li><li>كنت تعاني من انخفاض حجم الدم (مع انخفاض ضغط الدم). قد يحدث انهيار في الدورة الدموية بسهولة أكبر.</li><li>كنت تعاني من مشاكل في الدورة الدموية، مثل شحوب أصابعك (مرض رينود) أو ألم، تعب وأحياناً آلام حارقة في ساقيك.</li><li>كنت تعاني من مشاكل في الكلى. إذا كنت تعاني من مرض في الكلى أو كنت بحاجة لغسيل الكلى، فقد تصاب بارتفاع مستويات البوتاسيوم في الدم (فرط بوتاسيوم الدم). قد يسبب مشاكل خطيرة في القلب.</li><li>كان لديك أي حساسية أو معرض لخطر حدوث تفاعلات تأقية (تفاعلات حساسية حادة). قد يزيد إيسمولول من شدة الحساسية ويصبح العلاج أكثر صعوبة.</li><li>كان لديك أنت أو أي من أفراد عائلتك تاريخ مرضي بالصدفية (حيث تظهر على جلدك بقع متقشرة).</li><li>كنت تعاني من مرض يُسمى فرط الدرقية (فرط نشاط الغدة الدرقية).</li></ul><p>عادة لا يكون تغيير الجرعة ضرورياً إذا كنت تعاني من مشاكل في الكبد.</p><p>إذا كان ينطبق عليك أي مما سبق (أو لم تكن متأكداً)، فاستشر طبيبك أو الممرض قبل إعطائك هذا الدواء. قد تحتاج إلى فحصك بعناية وقد يتم تغيير علاجك.</p><p><strong>&nbsp;الأدوية الأخرى وإيزوبلوك</strong></p><p dir="RTL">أخبر طبيبك، الممرض أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أية أدوية أخرى. ويشمل ذلك الأدوية التي حصلت عليها بنفسك، بدون وصفة طبية، بما في ذلك الأدوية العشبية والمستحضرات الطبيعية. سيتحقق طبيبك من أن الأدوية الأخرى التي تأخذها لن تؤثر على طريقة عمل إيزوبلوك.</p><p>&nbsp;أخبر الطبيب أو الممرض إذا كنت تتناول أيّ مما يلي على وجه الخصوص:</p><ul dir="rtl"><li>الأدوية التي يمكن أن تخفض ضغط الدم أو تبطئ معدل ضربات القلب.</li><li>الأدوية المستخدمة لعلاج مشاكل نظم القلب أو آلام الصدر (الذبحة الصدرية) مثل فيراباميل وديلتيازيم. يجب ألا يتم إعطائك إيزوبلوك خلال 48 ساعة من إيقاف فيراباميل.</li><li>نيفيديبين، الذي يستخدم لعلاج آلام الصدر (الذبحة الصدرية)، وارتفاع ضغط الدم ومرض رينود.</li><li>الأدوية المستخدمة لعلاج مشاكل نظم القلب (مثل كينيدين، ديسوبيراميد، أميودارون) ولعلاج فشل القلب (مثل الديجوكسين، الديجيتوكسين، الديجيتال).</li><li>الأدوية المستخدمة لعلاج مرض السكري، بما في ذلك الأنسولين والأدوية التي تؤخذ عن طريق الفم.</li><li>الأدوية المعروفة باسم عامل محصر العقد (مثل تريمثافان).</li><li>الأدوية المستخدمة كمسكنات للألم، مثل مضادات الالتهاب غير الستيرويدية.</li><li>فلوكتافينين، وهو مسكن للألم.</li><li>أميسولبريد، وهو دواء يستخدم لعلاج المشاكل العقلية.</li><li>الأدوية المضادة للاكتئاب ثلاثية الحلقات (مثل إيميبرامين وأميتريبتيلين) أو أي أدوية أخرى لمشاكل الصحة العقلية.</li><li>الباربيتورات (مثل الفينوباربيتال، المستخدمة لعلاج الصرع) أو الفينوثيازين (مثل الكلوربرومازين، المستخدم لعلاج الاضطرابات العقلية).</li><li>كلوزابين الذي يُستخدم لعلاج الاضطرابات العقلية.</li><li>إبينفرين، الذي يستخدم لعلاج ردود الفعل التحسسية.</li><li>الأدوية التي تُستخدم لعلاج الربو.</li><li>الأدوية المستخدمة لعلاج نزلات البرد أو انسداد الأنف، تسمى &quot;مزيلات احتقان الأنف&quot;.</li><li>ريزيربين، الذي يُستخدم لعلاج ارتفاع ضغط الدم.</li><li>كلونيدين، الذي يستخدم لعلاج ارتفاع ضغط الدم والصداع النصفي.</li><li>موكسونيدين، الذي يُستخدم لعلاج ارتفاع ضغط الدم.</li><li>مشتقات الأرغوت، الأدوية المستخدمة غالباً لعلاج مرض باركنسون.</li><li>وارفارين، الذي يُستخدم لترقيق الدم.</li><li>مورفين، وهو مسكن قوي للألم.</li><li>كلوريد السوكساميثونيوم (المعروف أيضاً باسم سكسينيل كولين أو سكولين) أو ميفاكوريوم، والتي تستخدم لإرخاء عضلاتك، عادةً أثناء الجراحة. سيولي طبيبك أيضاً عناية خاصة عند استخدام إيزوبلوك أثناء العمليات الجراحية، عند تخديرك وعند العلاجات الأخرى.</li></ul><p>إذا لم تكن متأكداً إذا كان أي مما ذُكِرَ أعلاه ينطبق عليك، فاستشر الطبيب، الممرض أو الصيدلي قبل أخذ إيزوبلوك.</p><p><strong>&nbsp;</strong><em>الفحوصات التي قد تجريها أثناء استخدام إيزوبلوك</em></p><p dir="RTL">يمكن أن يؤدي استخدام الأدوية مثل إيزوبلوك لفترة طويلة إلى انخفاض في قوة ضربات قلبك.</p><p><strong>&nbsp;</strong>ونظراً لان إيزوبلوك يُستخدم لفترة محدودة فقط، فمن غير المحتمل أن يحدث لك ذلك. ستتم مراقبتك بعناية، أثناء العلاج، وسيتم تقليل العلاج باستخدام إيزوبلوك أو إيقافه إذا انخفضت قوة ضربات قلبك.</p><p>سيفحص طبيبك أيضاً ضغط دمك أثناء علاجك باستخدام إيزوبلوك.</p><p><strong>الحمل</strong> <strong>والرضاعة </strong></p><p dir="RTL">استشيري الطبيب أو الصيدلي قبل تناول أية أدوية.</p><p>لا ينبغي إعطائك إيزوبلوك إذا كنت حاملاً، أو تعتقدين بأنك حامل.</p><p>أخبري طبيبك إذا كنتِ ترضعين. قد يتسرب إيسمولول إلى حليب الثدي، لذلك لا ينبغي إعطائك إيزوبلوك إذا كنتِ ترضعين.</p><p><strong>يحتوي إيزوبلوك على الصوديوم</strong><strong> </strong></p><p dir="RTL">يحتوي إيزوبلوك على الصوديوم. تحتوي كل زجاجة على 0.206 ملمول (4.738 ملغم) صوديوم.<strong> </strong>يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">سيقرر طبيبك مقدار الدواء الذي ستحتاج إليه ومدة إعطائه لك. لا يتم إعطاء إيزوبلوك عادةً لمدة تزيد عن 24 ساعة.</p><p><strong>طريقة إعطاء إيزوبلوك</strong></p><p dir="RTL">إيزوبلوك محلول جاهز للاستخدام. سيتم إعطاؤك إيزوبلوك عن طريق الحقن البطيء (التسريب) من خلال إبرة يتم إدخالها في الوريد في ذراعك.</p><p>يجب عدم خلط إيزوبلوك مع بيكربونات الصوديوم أو أي مستحضرات دوائية أخرى.</p><ul dir="rtl"><li>يُؤخذ العلاج على مرحلتين:</li></ul><p dir="RTL">-&nbsp;المرحلة الأولى: جرعة كبيرة تُعطى على مدى دقيقة واحدة. يزيد هذا من المستويات في دمك بسرعة.&nbsp;</p><p dir="RTL">-&nbsp;المرحلة الثانية: جرعة أصغر تُعطى بعد ذلك على مدى أربع دقائق.&nbsp;</p><p dir="RTL">-&nbsp;يمكن بعد ذلك تكرار المرحلة الأولى والثانية وتعديلها وفقاً لاستجابة قلبك. بمجرد حدوث تحسن، سيتم إيقاف المرحلة الأولى (الجرعة الكبيرة) وسيتم تقليل المرحلة الثانية (الجرعة الصغيرة) حسب الضرورة.&nbsp;</p><p dir="RTL">-&nbsp;بعد الوصول إلى حالة مستقرة، قد يتم إعطاؤك دواءً آخر للقلب، مع تقليل جرعتك من إيزوبلوك تدريجياً.</p><ul dir="rtl"><li>إذا زاد معدل ضربات القلب أو ضغط الدم أثناء العملية الجراحية أو بعد التعافي منها مباشرة، فسيتم إعطاؤك جرعات أكبر من إيزوبلوك لفترة قصيرة.</li></ul><p><strong>كبار السن</strong></p><p dir="RTL">سيبدأ طبيبك علاجك بجرعة أقل.</p><p><strong>&nbsp;الأطفال</strong></p><p dir="RTL">يجب ألا يأخذ الأطفال إيزوبلوك حتى سن 18 عاماً.</p><p><strong>&nbsp;إذا أخذت جرعة زائدة من إيزوبلوك</strong></p><p dir="RTL">نظراً لأن من يعطيك إيزوبلوك هو شخص مدرب ومؤهل، فمن غير المحتمل أن تأخذ جرعة زائدة. ومع ذلك، إذا حدث هذا، فسوف يوقف الطبيب إيزوبلوك ويعطيك علاجاً إضافياً، عند الضرورة.</p><p><strong>&nbsp;إذا نسيت أخذ<strong> </strong>إيزوبلوك</strong></p><p dir="RTL">نظراً لأن من يعطيك إيزوبلوك هو شخص مدرب ومؤهل، فمن غير المحتمل أن تفوتك جرعة. ومع ذلك، إذا كنت تعتقد أنك قد فاتتك جرعة، فتحدث إلى طبيبك، الممرض أو الصيدلي في أقرب وقت ممكن.</p><p><strong>إذا توقفت عن أخذ إيزوبلوك</strong></p><p dir="RTL">قد يؤدي التوقف المفاجئ عن أخذ إيزوبلوك إلى ظهور أعراض تسارع ضربات القلب (تسارع القلب) وارتفاع ضغط الدم (فرط ضغط الدم). ولتجنب ذلك، يجب على طبيبك أن يوقف علاجك تدريجياً. إذا كان من المعروف أنك مصاب بمرض الشريان التاجي (قد يكون هذا مرتبطاً بتعرضك مسبقاً لذبحة صدرية أو لنوبة قلبية) فسوف يأخذ طبيبك الحذر الشديد عند إيقاف العلاج باستخدام إيزوبلوك.</p><p>إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب،&nbsp; الممرض أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. تختفي معظم الآثار الجانبية خلال 30 دقيقة من التوقف عن العلاج باستخدام إيسمولول.</p><p><strong><em>تم الإبلاغ عن الآثار الجانبية التالية مع إيسمولول: </em></strong></p><p dir="RTL">أخبر طبيبك أو الممرض على الفور إذا لاحظت أي من الآثار الجانبية التالية، والتي قد تكون خطيرة. قد يلزم أيضاً إيقاف التسريب.</p><p><strong>شائعة جدًا (قد تؤثر على أكثر من شخص من بين كل 10 أشخاص)</strong></p><ul dir="rtl"><li>هبوط في ضغط الدم. يمكن علاج ذلك بسرعة عن طريق تقليل جرعة إيسمولول أو إيقاف العلاج به. سيتم قياس ضغط الدم لديك كثيراً أثناء العلاج.</li><li>فرط التعرق.&nbsp;</li></ul><p><strong>شائعة (تؤثر على أقل من شخص من بين كل 10 أشخاص)</strong></p><ul dir="rtl"><li>فقدان الشهية.</li><li>الشعور بالقلق أو الاكتئاب.</li><li>دوخة.</li><li>الشعور بالنعاس.</li><li>صداع.</li><li>الشعور بوخز أو &rsquo;شعور مثل الدبابيس والإبر&lsquo;.</li><li>صعوبة التركيز.</li><li>الشعور بالاضطراب أو الاهتياج.</li><li>الشعور أو الإصابة بالمرض (الغثيان والقيء).</li><li>الشعور بالضعف.</li><li>الشعور بالتعب (الإرهاق).</li><li>تهيج وتصلب جلدك في موضع حقن إيسمولول.</li></ul><p><strong>غير شائعة (قد تؤثر على أقل من شخص من بين كل 100 شخص)</strong></p><ul dir="rtl"><li>أفكار غير طبيعية.</li><li>فقدان الوعي المفاجئ.</li><li>الشعور بالإغماء أو الإغماء.</li><li>النوبات (نوبات الصرع أو التشنجات).</li><li>مشاكل في الكلام.</li><li>مشاكل في الإبصار.</li><li>انخفاض معدل ضربات القلب.</li><li>مشاكل في الرسائل الكهربائية التي تتحكم في ضربات قلبك.</li><li>زيادة الضغط في شرايين الرئتين.</li><li>عجز القلب على ضخ كمية كافية من الدم (فشل القلب).</li><li>اضطراب في نظم القلب يُعرف أحياناً بالخفقان (انقباضات خارجة بطينية).</li><li>اضطراب ضربات القلب (نظم عُقدي).</li><li>شعور بعدم الراحة في الصدر ناتج من ضعف تدفق الدم عبر الأوعية الدموية لعضلة القلب (الذبحة الصدرية).</li><li>ضعف الدورة الدموية في ذراعيك أو ساقيك.</li><li>تبدو شاحباً أو متوهجاً.</li><li>وجود سوائل على رئتيك.</li><li>ضيق في النفس أو ضيق في الصدر يجعل التنفس صعباً.</li><li>صفير.</li><li>انسداد الأنف.</li><li>أصوات طقطقة/قرقعة غير طبيعية عند التنفس.</li><li>تغيرات في حاسة التذوق لديك.</li><li>عسر الهضم.</li><li>الإمساك.</li><li>جفاف الفم.</li><li>ألم في منطقة المعدة لديك.</li><li>تشوه الجلد.</li><li>احمرار الجلد.</li><li>ألم في العضلات أو الأوتار، يشمل حول عظام الكتف والأضلاع.</li><li>مشاكل عند التبول (احتباس البول).</li><li>الشعور بالبرد أو ارتفاع في درجة الحرارة (حمى).</li><li>ألم وتورم (وذمة) في الوريد في موضع حقن إيسمولول.</li><li>الشعور بالحرقة أو الكدمات في موضع الحقن.</li></ul><p><strong>نادرة جداً (قد تؤثر على أقل من شخص من بين كل 10000 شخص)</strong></p><ul dir="rtl"><li>انخفاض شديد في معدل ضربات القلب (توقف جيبي المنشأ).</li><li>انعدام النشاط الكهربائي في القلب (توقف الانقباض).</li><li>ألم في الأوعية الدموية مع وجود منطقة من الجلد الأحمر الساخن (التهاب الوريد الخثاري).</li><li>الجلد الميت الناتج من المحلول المتسرب حول موضع الحقن.</li></ul><p><strong>&nbsp;غير معروفة</strong> <strong>(عدد الأشخاص المصابين غير معروف)</strong></p><ul dir="rtl"><li>زيادة مستويات البوتاسيوم في الدم (فرط بوتاسيوم الدم).</li><li>زيادة مستويات الأحماض في الجسم (الحماض الأيضي).</li><li>زيادة معدل انقباض القلب (تسارع النظم البطيني الذاتي).</li><li>تشنج الشريان في القلب.</li><li>فشل الدورة الدموية الطبيعية (السكتة القلبية).</li><li>الصدفية (عند وجود بقع متقشرة على جلدك).</li><li>تورم في جلد الوجه، الأطراف، اللسان أو الحلق (وذمة وعائية).</li><li>الشرى (أرتيكاريا).</li><li>التهاب في الوريد أو ظهور تقرحات في موضع التسريب.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 25&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.&nbsp;</p><p dir="RTL">عند فتح المستحضر يكون مستقراً لمدة 24 ساعة في درجة حرارة من 2 إلى 8&deg; مئوية. مع ذلك، يجب استخدامه على الفور بعد الفتح.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد الإيسمولول. يحتوي كل 10 مللتر على هيدروكلوريد الإيسمولول يكافئ 100 ملغم إيسمولول.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي أسیتات الصودیوم ثلاثي الماء، حمض الأسيتيك الثلجي، هيدروكسيد الصوديوم و/أو هيدروكلوريد وماء معد للحقن. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">إيزوبلوك 100 ملغم/10 مللتر محلول للحقن هو محلول صافٍ، عديم اللون مائل للأصفر الفاتح في زجاجات كهرمانية من النوع رقم 1 بسعة 10 مللتر مع سدادات مطاطية رمادية وأغطية من الألومنيوم.</p><p style="text-align:right">حجم العبوة: زجاجة واحدة (10 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم&nbsp;8,8A e 8B&nbsp;فارفانسا<br />906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2020/12، رقم النسخة: SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esobloc 100 mg/10 ml Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 10 ml contains esmolol hydrochloride equivalent to 100 mg esmolol. 

Excipient with known effect: Sodium. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.  

Clear, colourless to light yellow solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Supraventricular tachycardia (except for pre-excitation syndromes) or noncompensatory sinus tachycardia</li></ul><p>Esobloc is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.</p><p>Esobloc is also indicated for non-compensatory sinus tachycardia where, in the physician&rsquo;s judgement the rapid heart rate requires specific intervention.</p><ul><li>Tachycardia and hypertension occurring in the perioperative phase</li></ul><p>Treatment of tachycardia and hypertension that occur during induction of anesthesia and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician&rsquo;s judgment such specific intervention is considered indicated.</p><p>Esobloc is not indicated for use in children aged up to 18 years (see section 4.2).</p><p>Esobloc is not intended for use in chronic settings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p>Esobloc 100 mg/10 ml Solution for Injection is a ready-to-use 10 mg/ml solution recommended for intravenous administration.</p><p>This dosage form is used to administer the appropriate Esobloc loading dose or bolus dose by hand-held syringe.</p><p><strong>SUPRAVENTRICULAR TACHYARRYTHMIA (except for pre-excitation syndromes) OR NON-COMPENSATORY SINUS TACHYCARDIA</strong></p><p>The Esobloc dosage in supraventricular tachyarrhythmias should be individually titrated as indicated in the below flow chart. &nbsp;</p><p><strong>Flow Chart for Initiation and Maintenance of Treatment &nbsp;</strong></p><p><img src="data:image/png;base64,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" alt="" width="573" height="539" vspace="0" hspace="0" border="0" style="width:573px;height:539px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><u>Loading dose</u></p><p>Loading dose adjustment may be necessary depending on the haemodynamic response (heart rate, blood pressure).</p><p><strong>&nbsp;</strong><u>Maintenance dose</u></p><p>For a continuous and progressive dosage an effective maintenance dose is between 50 to 200 micrograms/kg/minute. 25 micrograms/kg/minute doses may be used.</p><p>Maintenance dose adjustment may be necessary depending on the desired haemodynamic response.</p><p>Administration of doses greater than 200 mcg/kg/min provides little added heart ratelowering effect, and the rate of adverse reactions increases.</p><p>Loading dose and maintenance doses of Esobloc to administer for different patient weights are outlined in Table 1 and Table 2 respectively. &nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;Table 1: Volume of esmolol 10 mg/ml required for an initial loading dose of 500 mcg/kg/minute </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="9" style="vertical-align:top"><p style="text-align:center"><strong>Patient weight (kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>120</p></td></tr><tr><td style="vertical-align:top"><p><strong>Volume (ml)</strong></p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>6</p></td></tr></tbody></table><p><strong>Table 2: Volume of esmolol 10 mg/ml required to provide maintenance doses at infusion rates between 12.5 and 300 mcg/kg/minute </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="7" style="vertical-align:top"><p style="text-align:center"><strong>Infusion Dose Rate (mcg/kg/min)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>12.5</strong></p></td><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p><strong>100</strong></p></td><td style="vertical-align:top"><p><strong>150</strong></p></td><td style="vertical-align:top"><p><strong>200</strong></p></td><td style="vertical-align:top"><p><strong>300</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patient Weight (kg)</strong></p></td><td colspan="7" style="vertical-align:top"><p><strong>Amount to administer per hour to achieve the dose rate (ml/hr)</strong></p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>72</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>3.75</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>108</p></td></tr><tr><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>5.25</p></td><td style="vertical-align:top"><p>10.5</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>126</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>144</p></td></tr><tr><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>6.75</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>81</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>162</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>180</p></td></tr><tr><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>8.25</p></td><td style="vertical-align:top"><p>16.5</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>66</p></td><td style="vertical-align:top"><p>99</p></td><td style="vertical-align:top"><p>132</p></td><td style="vertical-align:top"><p>198</p></td></tr><tr><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>216</p></td></tr></tbody></table><p><strong>&nbsp;</strong>1 ml of Esobloc is equivalent to 10 mg of esmolol.</p><p>As the desired heart rate or safety end-point (e.g., lowered blood pressure) is approached, OMIT the loading dose and reduce the incremental dose in the maintenance infusion from 50 micrograms/kg/minute to 25 micrograms/kg/minute or lower. If necessary, the interval between the titration steps may be increased from 5 to 10 minutes. &nbsp;</p><p><strong>PERIOPERATIVE TACHYCARDIA AND HYPERTENSION</strong></p><p>For perioperative tachycardia and hypertension the dosing regimen may vary as follows:</p><p><em>For intraoperative treatment<strong> </strong></em>- during anaesthesia when immediate control is required:</p><ul><li>A bolus injection of 80 mg is given over 15 to 30 seconds followed by a 150 micrograms/kg/minute infusion. Titrate the infusion rate as required up to 300 micrograms/kg/minute. The volume of infusion required for different patient weights is provided in Table 2.</li></ul><p><em>&nbsp;Upon awakening from anaesthesia</em></p><ul><li>An infusion of 500 micrograms/kg/minute is given for 4 minutes followed by a 300 micrograms/kg/minute infusion. The volume of infusion required for different patient weights is provided in Table 2.</li></ul><p><em>For post-operative situations when time for titration is available</em></p><ul><li>A loading dose of 500 micrograms/kg/minute is given over 1 minute before each titration step to produce a rapid onset of action. Use titration steps of 50, 100, 150, 200, 250 and 300 micrograms/kg/minute given over 4 minutes and stopping at the desired therapeutic effect. The volume of infusion required for different patient weights is provided in Table 2.</li></ul><p><u>Recommended maximum dose:</u></p><ul><li>For adequate control of blood pressure, higher dosages (250-300 mcg/kg/min) may be required. The safety of dosages above 300 mcg/kg/min has not been adequately studied.</li></ul><p><strong>&nbsp;</strong><u>Potential effects to be aware of during dosing with Esobloc:</u></p><p>In the event of an adverse reaction, the dosage of Esobloc may be reduced or discontinued. Pharmacological adverse reactions should resolve within 30 minutes.</p><p>If a local infusion site reaction develops, an alternative infusion site should be used and caution should be taken to prevent extravasation.</p><p>The administration of Esobloc for longer than 24 hours has not been thoroughly evaluated. Infusion durations greater than 24 hours should only be used with caution.</p><p>It is advised to terminate the infusion gradually because of the risk of rebound tachycardia and rebound hypertension. As with all beta-blockers, because withdrawal effects cannot be excluded, caution should be used in abruptly discontinuing Esobloc administration in coronary artery disease (CAD) patients.</p><p><u>Replacing Esobloc therapy by alternative drugs</u></p><p>After patients achieve an adequate control of the heart rate and a stable clinical status, transition to alternative drugs (such as antiarrhythmics or calcium antagonists) may be accomplished.</p><p><strong><em>&nbsp;</em></strong><em>Reducing the dosage:</em></p><p>When Esobloc is to be replaced by alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of Esobloc as follows:</p><ul><li>Within the first hour after the first dose of the alternative drug, reduce the Esobloc infusion rate by one-half (50%).</li><li>After administration of the second dose of the alternative drug, monitor the patient&#39;s response and if satisfactory control is maintained for the first hour, discontinue the Esobloc infusion.</li></ul><p><strong>&nbsp;</strong><u>Additional dosing information</u></p><p>As the desired therapeutic effect or a safety endpoint (e.g., lowered blood pressure) is approached, omit the loading dose and reduce the incremental infusion to 12.5 to 25 micrograms/kg/minute.</p><p>Also, if desired, increase the interval between titration steps from 5 to 10 minutes.</p><p>Esobloc should be discontinued when heart rate or blood pressure rapidly approach or exceed a safety limit, and then restarted without a loading infusion at a lower dose after the heart rate or blood pressure has returned to an acceptable level.</p><p><strong>&nbsp;</strong><u>Special populations</u></p><p><em>Elderly</em></p><p>The elderly should be treated with caution, starting with a lower dosage.</p><p>Special studies in the elderly have not been conducted. However, analysis of data from 252 patients over 65 years of age indicated that no variations in pharmacodynamic effects occurred as compared with data from patients under 65.</p><p><em>&nbsp;Patients with renal insufficiency</em></p><p>In patients with renal insufficiency caution is needed when Esobloc is administered by infusion, since the acid metabolite of Esobloc is excreted unchanged through the kidneys. Excretion of the acid metabolite is significantly decreased in patients with end-stage renal disease, with the elimination half-life increased to about ten-fold that of normal, and plasma levels considerably elevated.</p><p><strong><em>&nbsp;</em></strong><em>Patients with liver insufficiency</em></p><p>In case of liver insufficiency no special precautions are necessary since the esterases in the red blood cells have a main role in the Esobloc metabolism.</p><p><strong><em>&nbsp;</em></strong><em>Paediatric population</em></p><p>The safety and efficacy of esmolol in children aged up to 18 years have not yet been established. Therefore, Esobloc is not indicated for use in the paediatric population (see section 4.1). Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to any of the excipients or other beta-blockers (cross sensitivity between beta-blockers is possible); 
• Severe sinus bradycardia (less than 50 beats per minute);
• Sick sinus syndrome; severe AV-nodal conductance disorders (without pacemaker); 2nd or 3rd degree AV-block;
• Cardiogenic shock;
• Severe hypotension;
• Decompensated heart failure;
• Concomitant or recent intravenous administration of verapamil. Esobloc must not be administered within 48 hours of discontinuing verapamil (see section 4.5);
• Non-treated phaeochromocytoma;
• Pulmonary hypertension;
• Acute asthmatic attack;
• Metabolic acidosis. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Warnings</strong></p><p>It is recommended to continuously monitor the blood pressure and the ECG in all patients treated with Esobloc.</p><p>The use of Esobloc for control of ventricular response in patients with supraventricular arrhythmias should be undertaken with caution when the patient is compromised haemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. Despite the rapid onset and offset of the effects of esmolol hydrochloride, severe reactions may occur, including loss of consciousness, cardiogenic shock, cardiac arrest. Several deaths have been reported in complex clinical states where esmolol hydrochloride was presumably being used to control ventricular rate.</p><p>The most frequently observed side effect is hypotension, which is dose related but can occur at any dose. This can be severe. In the event of a hypotensive episode the infusion rate should be lowered or, if necessary, be discontinued. Hypotension is usually reversible (within 30 minutes after discontinuation of administration of esmolol hydrochloride). In some cases, additional interventions may be necessary to restore blood pressure. In patients with a low systolic blood pressure, extra caution is needed when adjusting the dosage and during the maintenance infusion.</p><p>Bradycardia, including severe bradycardia, and cardiac arrest has occurred with the use of esmolol hydrochloride. Esobloc should be used with special caution in patients with low pretreatment heart rates and only when the potential benefits are considered to outweigh the risk.</p><p>Esobloc is contraindicated in patients with pre-existing severe sinus bradycardia (see section 4.3). If the pulse rate decreases to less than 50- 55 beats per minute at rest and the patient experiences symptoms related to bradycardia, the dosage should be reduced or administration stopped.</p><p>Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure. Beta-blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure.</p><p>Caution should be exercised when using Esobloc in patients with compromised cardiac function. At the first sign or symptom of impending cardiac failure, Esobloc should be withdrawn. Although withdrawal may be sufficient because of the short elimination half-life of esmolol hydrochloride, specific treatment may also be considered (see section 4.9). Esobloc is contraindicated in patients with decompensated heart failure (see section 4.3).</p><p>Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block or other cardiac conduction disturbances (see section 4.3).</p><p>Esobloc should be used with caution and only after pre-treatment with alpha-receptor blockers in patients with pheochromocytoma (see section 4.3).</p><p>Caution is required when Esobloc is used to treat hypertension following induced hypothermia.</p><p>Patients with bronchospastic disease should, in general, not receive betablockers. Because of its relative beta-1 selectivity and titratability, Esobloc should be used with caution in patients with bronchospastic diseases. However, since beta-1 selectivity is not absolute, Esobloc should be carefully titrated to obtain the lowest possible effective dose. In the event of bronchospasm, the infusion should be terminated immediately and a beta-2-agonist should be administered if necessary.</p><p>If the patient already uses a beta-2-receptor stimulating agent, it may be necessary to re-evaluate the dose of this agent.</p><p>Esobloc should be used with caution in patients with a history of wheezing or asthma.</p><p><strong>Precautions</strong></p><p>Esobloc should be used with caution in diabetics or in case of suspected or actual hypoglycaemia. Beta-blockers may mask the prodromal symptoms of a hypoglycaemia such as tachycardia. However, dizziness and sweating may not be affected. Concomitant use of beta-blockers and antidiabetic agents can increase the effect of the antidiabetic agents (blood glucose&ndash;lowering) (see section 4.5).</p><p>Infusion site reactions have occurred with the use of both esmolol hydrochloride 10 mg/ml and 20 mg/ml. These reactions have included infusion site irritation and inflammation as well as more severe reactions such as thrombophlebitis, necrosis, and blistering, in particular when associated with extravasation (see section 4.8). Infusions into small veins or through a butterfly catheter should be avoided. If a local infusion site reaction develops, an alternative infusion site should be used.</p><p>Beta-blockers may increase the number and the duration of anginal attacks in patients with Prinzemetal&rsquo;s angina due to unopposed alpha-receptor mediated coronary artery vasoconstriction. Non-selective beta-blockers should not be used for these patients and beta-1 selective blockers should only be used with the utmost care.</p><p>In hypovolemic patients, esmolol hydrochloride can attenuate reflex tachycardia and increase the risk of circulatory collapse. Therefore, Esobloc should be used with caution in such patients.</p><p>In patients with peripheral circulatory disorders (Raynaud&rsquo;s disease or syndrome, intermittent claudication), beta-blockers should be used with great caution as aggravation of these disorders may occur.</p><p>Some beta-blockers, especially those administered intravenously, including esmolol hydrochloride, have been associated with increases in serum potassium levels and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment and those on haemodialysis.</p><p>Beta-blockers may increase both the sensitivity toward allergens and the seriousness of anaphylactic reactions. Patients using beta-blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions (see section 4.5).</p><p>Beta-blockers have been associated with the development of psoriasis or psoriasiform eruptions and with aggravation of psoriasis. Patients with a personal or family history of psoriasis should be administered betablockers only after careful consideration of expected benefits and risks.</p><p>Beta-blockers, such as propranolol and metoprolol, may mask certain clinical signs of hyperthyroidism (such as tachycardia). Abrupt withdrawal of existing therapy with beta-blockers in patients at risk or suspected of developing thyrotoxicosis may precipitate thyroid storm and these patients must be monitored closely.</p><p><strong>Esobloc<strong> </strong>contains sodium </strong></p><p>Esobloc contains sodium. Each vial contains 0.206 mmol (4.738 mg) sodium.<strong> </strong>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Care should always be exercised whenever Esobloc is used with other antihypertensive agents or other drugs that may cause hypotension or bradycardia: the effects of esmolol hydrochloride may be enhanced or the side-effects of hypotension or bradycardia may be exacerbated.</p><p>Calcium antagonists such as verapamil and to a lesser extent diltiazem have a negative influence on contractility and AV conduction. The combination should not be given to patients with conduction abnormalities and Esobloc should not be administered within 48 hours of discontinuing verapamil (see section 4.3).</p><p>Calcium antagonists such as dihydropyridine derivatives (e.g., nifedipine) may increase the risk of hypotension. In patients with cardiac insufficiency and who are being treated with a calcium antagonist, treatment with beta-blocking agents may lead to cardiac failure. Careful titration of Esobloc and appropriate haemodynamic monitoring is recommended.</p><p>Concomitant use of Esobloc and Class I anti-arrhythmic drugs (e.g., disopyramide, quinidine) and amiodarone may have potentiating effect on atrial-conduction time and induce negative inotropic effect.</p><p>Concomitant use of Esobloc and insulin or oral anti-diabetic drugs may intensify the blood sugar lowering effect (especially non-selective beta-blockers). Beta-adrenergic blockade may prevent the appearance of signs of hypoglycaemia (tachycardia), but other manifestations such as dizziness and sweating may not be masked.</p><p>Anaesthetic drugs: in situations where the patient&rsquo;s volume status is uncertain or concomitant antihypertensive drugs are utilized, there may be attenuation of the reflex tachycardia and an increased the risk of hypotension. Continuation of beta-blockade reduces the risk of arrhythmia during induction and intubation. The anaesthetist should be informed when the patient is receiving a beta-blocking agent in addition to Esobloc. The hypotensive effects of inhalation anaesthetic agents may be increased in the presence of Esobloc. The dosage of either agent may be modified as needed to maintain the desired haemodynamics.</p><p>The combination of Esobloc with ganglion blocking agents can enhance the hypotensive effect.</p><p>NSAIDs may decrease the hypotensive effects of beta-blockers.</p><p>Special caution must be taken when using floctafenine or amisulpride concomitantly with beta-blockers.</p><p>Concomitant administration of tricyclic antidepressants (such as imipramine and amitriptyline), barbiturates or phenothiazines (such as chlorpromazine), as well as other antipsychotic agents (such as clozapine) may increase the blood pressure lowering effect. Dosing of Esobloc should be adjusted downward to avoid unexpected hypotension.</p><p>When using beta-blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic). Patients using beta-blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions (see section 4.4).</p><p>The effects of Esobloc may be counteracted by sympathomimetic drugs having beta adrenergic</p><p>agonist activity with concomitant administration. The dose of either agent may need to be adjusted based on patient response, or use of alternate therapeutic agents considered.</p><p>Catecholamine-depleting agents, e.g., reserpine, may have an additive effect when given with beta-blocking agents. Patients treated concurrently with esmolol hydrochloride and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope or postural hypotension.</p><p>Use of beta-blockers with moxonidine or alpha-2-agonists (such as clonidine), increases the risk of withdrawal rebound hypertension. If clonidine or moxonidine are used in combination with a beta-blocker and both treatments have to be discontinued, the beta blocker should be discontinued first and then the clonidine or moxonidine after a few days.</p><p>The use of beta-blockers with ergot derivatives may result in severe peripheral vasoconstriction and hypertension.</p><p>Data from an interaction study between esmolol hydrochloride and warfarin showed that concomitant administration of esmolol and warfarin does not alter warfarin plasma levels. Esmolol hydrochloride concentrations, however, were equivocally higher when given with warfarin.</p><p>When digoxin and esmolol hydrochloride were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points. The combination of digitalis glycosides and esmolol hydrochloride may increase AV conduction time. Digoxin did not affect esmolol hydrochloride pharmacokinetics.</p><p>When intravenous morphine and esmolol hydrochloride interaction was studied in normal subjects, no effect on morphine blood levels was seen. The esmolol hydrochloride steady-state blood levels were increased by 46% in the presence of morphine, but no other pharmacokinetic parameters were changed.</p><p>The effect of esmolol hydrochloride on the duration of suxamethonium chloride-induced or mivacurium-induced neuromuscular blockade has been studied in patients undergoing surgery. Esmolol did not affect the onset of neuromuscular blockade by suxamethonium chloride, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes. Esmolol hydrochloride moderately prolonged the clinical duration (18.6%) and recovery index (6.7%) of mivacurium.</p><p>Although the interactions observed in studies of warfarin, digoxin, morphine, suxamethonium chloride or mivacurium are not of major clinical importance, esmolol should be titrated with caution in patients being treated concurrently with warfarin, digoxin, morphine, suxamethonium chloride or mivacurium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are limited amount of data from the use of esmolol hydrochloride in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Esmolol hydrochloride is not recommended during pregnancy.</p><p>Based on the pharmacological action, in the later period of pregnancy, side effects on the foetus and neonate (especially hypoglycemia, hypotension and bradycardia) should be taken into account.</p><p>If treatment with Esobloc is considered necessary, the uteroplacental blood flow and foetal growth should be monitored. The newborn infant must be closely monitored.</p><p><strong>Breastfeeding</strong></p><p>Esmolol hydrochloride should not be used during breast-feeding.</p><p>It is not known whether esmolol hydrochloride/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.</p><p><strong>Fertility</strong></p><p>There are no human data on the effects of esmolol hydrochloride on fertility.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of undesirable effects, the dose of esmolol can be reduced or discontinued.</p><p>Most of the undesirable effects observed have been mild and transient. The most important one has been hypotension. The following undesirable effects are ranked according to MedDRA System Organ Class (SOC) and to their frequency.</p><p>Note: The frequency of occurrence of adverse events is classified as follows:</p><p>Very common (&ge; 1/10)</p><p>Common (&ge; 1/100 to &lt; 1/10)</p><p>Uncommon (&ge; 1/1000 to &lt; 1/100)</p><p>Very rare (&lt;1/10000)</p><p>Not known (Cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p style="text-align:center"><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Very common</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>common</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Very rare</strong></p></td><td style="vertical-align:top"><p style="text-align:center"><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalemia</p><p>Metabolic acidosis</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Anxiety</p></td><td style="vertical-align:top"><p>Thinking abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizzines<sup>1 </sup></p><p>Somnolence</p><p>Headache</p><p>Paraesthesiae</p><p>Disturbance in attention</p><p>Confusional state</p><p>Agitation</p></td><td style="vertical-align:top"><p>Syncope</p><p>Convulsion</p><p>Speech disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bradycardia</p><p>Atrioventricular block</p><p>Pulmonary arterial pressure increased</p><p>Cardiac failure</p><p>Ventricular extrasystoles</p><p>Nodal rhythm</p><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Sinus arrest</p><p>Asystole</p></td><td style="vertical-align:top"><p>Accelerated idioventricular rhythm</p><p>Coronary arteriospasm</p><p>Cardiac arrest</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral ischaemia</p><p>Pallor</p><p>Flushing</p></td><td style="vertical-align:top"><p>Thrombophlebitis<sup>2</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>Dizziness and diaphoresis are in association with symptomatic hypotension.</p><p><sup>2</sup>In association with Injection and Infusion site reactions.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known </strong></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic</p><p>and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Pulmonary oedema</p><p>Bronchospasm</p><p>Wheezing</p><p>Nasal congestion</p><p>Rhonchi</p><p>Rales</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p></td><td style="vertical-align:top"><p>Dysgeusia</p><p>Dyspepsia</p><p>Constipation</p><p>Dry mouth</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Diaphoresis<sup>1</sup></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Skin</p><p>discolouration<sup>2</sup></p><p>Erythema<sup>2</sup></p></td><td style="vertical-align:top"><p>Skin necrosis<sup>2</sup></p><p>(due to extravasation)</p></td><td style="vertical-align:top"><p>Psoriasis<sup>3</sup></p><p>Angioedema</p><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and</p><p>connective tissue</p><p>disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Musculoskeletal</p><p>pain<sup>4</sup></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary</p><p>disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site</p><p>conditions</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Asthenia</p><p>Fatigue</p><p>Injection site reaction</p><p>Infusion site reaction</p><p>Infusion site inflammation</p><p>Infusion site induration</p></td><td style="vertical-align:top"><p>Chills</p><p>Pyrexia</p><p>Oedema<sup>2</sup></p><p>Pain<sup>2</sup></p><p>Infusion site burning</p><p>Infusion site ecchymosis</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Infusion site phlebitis</p><p>Infusion site vesicles</p><p>Blistering<sup>2</sup></p></td></tr></tbody></table><p><sup>1</sup><strong> </strong>Dizziness and diaphoresis are in association with symptomatic hypotension.</p><p><sup>2</sup><strong> </strong>In association with Injection and Infusion site reactions.</p><p><sup>3</sup><strong> </strong>Beta-blockers as a drug class can cause psoriasis in some situations, or worsen it.</p><p><sup>4</sup><strong> </strong>Including midscapular pain and costochondritis</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions &lt;via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li><strong>&nbsp;</strong>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of massive accidental overdoses with concentrated solutions of esmolol hydrochloride have occurred. Some of these overdoses have been fatal while others have resulted in permanent disability. Loading doses in the range of 625 mg to 2.5 g (12.5 to 50 mg/kg) have been fatal.</p><p><strong>Symptoms</strong></p><p>In case of overdose the following symptoms can occur: severe hypotension, sinus bradycardia, atrioventricular block, heart insufficiency, cardiogenic shock, cardiac arrest, bronchospasm, respiratory insufficiency, loss of consciousness to coma, convulsions, nausea, vomiting, hypoglycaemia and hyperkalaemia.</p><p><strong>Treatment </strong></p><p>Because of the short elimination half-life of esmolol (approximately 9 minutes), the first step in the management of toxicity should be to discontinue the administration of the drug. The time taken for symptoms to disappear following overdosing will depend on the amount of esmolol hydrochloride<strong> </strong>administered. This may take longer than the 30 minutes seen with discontinuation at therapeutic dose levels of esmolol hydrochloride. Artificial respiration may be necessary. Based on the observed clinical effects, the following general measures should also be considered:</p><p><em>Bradycardia:</em> Atropine or another anticholinergic drug should be given i.v. When the bradycardia cannot be treated sufficiently a pacemaker may be necessary.</p><p><em>Bronchospasm:</em> Nebulised beta-2-sympathomimetics should be given. If this is not sufficient intravenous beta-2-sympathomimetics or aminophylline can be considered.</p><p><em>Symptomatic hypotension:</em> Fluids and/or pressor agents should be given i.v.</p><p><em>Cardiovascular depression or cardiac shock:</em> Diuretics or sympathomimetics can be administered. The dose of sympathomimetics (depending on the symptoms: dobutamine, dopamine, noradrenaline, isoprenaline, etc.) depends on the therapeutic effect.</p><p>In case further treatment is necessary, the following agents can be given i.v. based on the clinical situation and judgment of the treating healthcare professional:</p><ul><li>Atropine;</li><li>Inotropic agents;</li><li>Calcium ions.</li></ul>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Beta-blocking agents, selective.</p><p>ATC code: C07AB09</p><p>Esobloc is a beta-selective (cardioselective) adrenergic receptor blocking agent. At therapeutic doses esmolol hydrochloride has no significant intrinsic sympathomimetic activity (ISA) or membrane stabilising activity.</p><p>Esmolol hydrochloride, the active ingredient of Esobloc, is chemically related to the phenoxy propanolamine class of beta-blockers.</p><p>Based on the pharmacological properties esmolol has a rapid onset and a very short duration of action by which the dose can be quickly adjusted.</p><p>When an appropriate loading dose is used, steady state blood levels are obtained within 5 minutes. However, the therapeutic effect is achieved sooner than the stable plasma concentration. The infusion rate can then be adjusted to obtain the desired pharmacological effect.</p><p>Esmolol hydrochloride has the known haemodynamic and electrophysiologic effect of betablockers:</p><ul><li>Reduction of the heart frequency during rest and exercise;</li><li>Reduction of the isoprenaline caused increase of the heart frequency;</li><li>Increase of the recovering time of the SA-node;</li><li>Delay of the AV-conductance;</li><li>Prolonging the AV-interval with normal sinus rhythm and during atrium stimulation without delay in the His-Purkinje tissue;</li><li>Prolonging of PQ time, induction of AV block grade II;</li><li>Prolonging the functional refractory period of atria and ventricles;</li><li>Negative inotropic effect with decreased ejection fraction;</li><li>Decrease in blood pressure.&nbsp;</li></ul><p><strong>Children</strong></p><p>An uncontrolled pharmacokinetic/efficacy study was undertaken in 26 paediatric patients aged 2 to 16 years with supraventricular tachycardia (SVT). A loading dose of 1000 micrograms/kg of esmolol hydrochloride was administered followed by a continuous infusion of 300 micrograms/kg/minute. SVT was terminated in 65% of patients within 5 minutes of the commencement of esmolol hydrochloride.</p><p>In a randomised but uncontrolled dose comparison study, efficacy was assigned in 116 paediatric patients aged 1 week to 7 years with hypertension following repair of coarctation of the aorta. Patients receiving an initial infusion of either 125 micrograms/kg, 250 micrograms/kg, or 500 micrograms/kg, followed by a continuous infusion of 125 micrograms/kg/minute, 250 micrograms/kg/minute, or 500 micrograms/kg/minute respectively. There was no significant difference in hypotensive effect between the 3 dosage groups. 54% of patients overall required medication other than esmolol hydrochloride to achieve satisfactory blood pressure control. No difference was apparent in this regard between the different dose groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>The kinetics of esmolol are linear in healthy adults, the plasma concentration is proportional to the dose. If a loading dose is not used then steady-state blood concentrations are reached within 30 minutes with doses of 50 to 300 micrograms/Kg per minute.</p><p><strong>Distribution</strong></p><p>The distribution half-life of esmolol hydrochloride is very fast, about 2 minutes.</p><p>The volume of distribution is 3.4 l/kg. Esmolol hydrochloride is 55% bound to human plasma protein compared with only 10% for the acid metabolite.</p><p><strong>Biotransformation</strong></p><p>The metabolism of esmolol hydrochloride is independent when the dose is between 50 and 300 micrograms/kg/minute.</p><p>Esmolol hydrochloride is metabolised by esterases into an acid metabolite (ASL- 8123) and methanol. This occurs through hydrolysis of the ester group by esterases in the red blood cells.</p><p><strong>Elimination</strong></p><p>The elimination half-life after intravenous administration is approximately 9 minutes. The total clearance is 285 ml/kg/minute; this is independent of the circulation of the liver or any other organ. Esmolol hydrochloride is excreted by the kidneys, partly unchanged (less than 2% of the administered amount), partly as acid metabolite that has a weak (less than 0.1% of esmolol) beta-blocking activity. The acid metabolite is excreted in the urine and has a half-life of about 3.7 hours.</p><p><strong>Children</strong></p><p>A pharmacokinetic study was undertaken in 22 paediatric patients aged 3 to 16 years. A loading dose of 1000 micrograms/kg of esmolol hydrochloride was administered, followed by a continuous infusion of 300 micrograms/kg/minute. The observed mean total body clearance was 119 ml/kg/minute, the mean volume of distribution 283 ml/kg and the mean terminal elimination half-life 6.9 minutes, indicating that esmolol hydrochloride kinetics in children are similar to those in adults. However, large inter-individual variability was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No teratogenic effect has been observed in animal studies. In rabbits an embryo toxic effect has been observed (increase in fetal resorption) which was probably caused by esmolol hydrochloride. This effect was observed at doses at least 10 times higher than the therapeutic dose. No studies have been done on the effect of esmolol hydrochloride on the fertility and on peri- and postnatal effects. Esmolol hydrochloride was found to be not mutagenic in several in vitro and in vivo test systems. The safety of esmolol hydrochloride has not been examined in long-term studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Sodium acetate trihydrate</li><li>Glacial acetic acid</li><li>NaOH and/or HCl</li><li>Water for injection</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products or sodium bicarbonate solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.  

The opened product is physicochemically stable for 24 hours at 2 to 8°C. 

From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless opening has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p><p>Store in the original package in order to protect from light.&nbsp; &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml type I amber glass vials with grey rubber stoppers and aluminum caps.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial is intended for single use only.</p><p>Avoid contact with alkali.</p><p>The solution should be visually inspected for particulate matter and discolouration prior to administration. Only a clear and colourless or slightly coloured solution should be used. Any unused solution and the containers should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07 December 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>